46
Participants
Start Date
January 31, 2016
Primary Completion Date
October 31, 2018
Study Completion Date
October 31, 2018
99mTc-3PRGD2
"Diagnostic group:For patients in suspicion of breast cancer, single intravenous bolus injection of nearly 0.3 mCi/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and lesions SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.~Efficacy evaluation group:patients firstly diagnose with malignant lesions ,and prepare to chemotherapy(including neoadjuvant chemotherapy) or radiotherapy.the same dose of 99mTc-3PRGD2 will be intravenously injected into the patients before treatment ,the second period,the sixth period( almost three months after the initial treatment),whole-body planar and lesions SPECT/CT to assess the value of 99mTc-3PRGD2 in evaluation of cancers."
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University, Fuzhou
First Affiliated Hospital of Fujian Medical University
OTHER